Skip to main content
Fig. 4 | BMC Gastroenterology

Fig. 4

From: Effectiveness and safety of vedolizumab induction with or without budesonide in patients with moderately to severely active Crohn’s disease in Europe: a retrospective observational study

Fig. 4

Time to clinical remission (days) according to patient-reported symptoms: APS (≤ 1) and LSF (≤ 3). PRO-2 is estimated as a sum of the weighted averages of APS and LSF. APS = abdominal pain score; BUD = budesonide; CI = confidence interval; LSF = loose stool frequency; VDZ = vedolizumab

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us